Mirtazapine for neuroleptic-induced akathisia.
Poyurovsky
M
M
Weizman
A
A
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D017109:Akathisia, Drug-Induced / Q000188:drug therapy*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000078785:Mirtazapine; D011618:Psychotic Disorders / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D014150:Antipsychotic Agents; D008803:Mianserin; D000078785:Mirtazapine; D006220:Haloperidol